Flyte is a company that offers an FDA-cleared, in-home treatment for stress urinary incontinence (SUI) in women. Their patented mechanotherapy, delivered through a medical-grade silicone wand, aims to strengthen and restore pelvic floor muscles, providing a safe and effective alternative to surgery.

Luke Dery

Flyte

Femtech company on a mission to cure bladder leaks with convenient, effective over-the-counter products that empower women.

Flyte is a simple, effective in-home treatment for stress urinary incontinence. Backed by strong clinical evidence, Flyte is FDA cleared for over-the-counter use. flytetherapy.com

Exciting News Alert!

Urology Times has published an interview discussing Flyte's US clinical trial titled "Mechanotherapy device shows efficacy for stress urinary incontinence"! https://loom.ly/GEZy2Yw

Check out the interview where the primary investigator of the study, Dr. Nissrine Nakib, Medical Director of Urology at M Health Fairview and Associate Professor of Female Urology and Urodynamics at the University of Minnesota, along with our CEO, Lydia Zeller, discuss the groundbreaking results with Flyte showcasing the efficacy of mechanotherapy for treating #StressUrinaryIncontinence! In particular, Dr. Nakib stresses the importance of #screening for and treating UI in #PrimaryCare and #OBGYN.

Thank you to Femtech Insider for featuring our landmark study proving the efficacy of the Flyte device in treating stress urinary incontinence and weakened pelvic floor muscles!

Pelvital remains committed to prioritizing women’s health by revolutionizing the treatment landscape, providing evidence-based options for clinicians, and empowering women to regain control over their lives.

https://loom.ly/A0lVmW8

We very proud to share that Therapeutic Advances in Urology has published our landmark paper, “Randomized trial of mechanotherapy for the treatment of stress urinary incontinence in women”.

Pelvital’s mission is to transform the standard of care for urinary incontinence, and this paper's publication marks a crucial milestone. It is our second clinical trial evidencing that our first product, the FDA-cleared, in-home device, Flyte, effectively treats stress urinary incontinence (SUI) and weakened pelvic floor muscles with 71% of study participants being dry or near dry over 2 to 12 weeks, results comparable to surgical intervention. 

Statistics show that 62 percent of women suffer from urinary incontinence, causing disruptions that range from inconvenient to debilitating. For generations, women have believed that it is a normal part of aging. We at Pelvital and leading medical community members including Dr. Nissrine Nakib, who co-authored this paper, know that isn’t the case. We’re thrilled to bring to them a solution they can use in the comfort and privacy of their own home that provides effective relief from the symptoms of incontinence.  

https://loom.ly/AbPfP4o 

Surgical-level Results. Without Surgery.  Listen to Flyte’s President & CEO, Lydia Zeller, discuss the shocking statistics behind urinary incontinence and how Flyte is transforming the standard of care for urinary incontinence using the therapeutic treatment modality of mechanotherapy. 

https://lnkd.in/ed6xAmfy 

Elevating the Conversation on Incontinence Treatment Options 

Caring for a loved one with #urinaryincontinence can be challenging, and the recent AARP article "Incontinence: How Family Caregivers Can Help Manage This Common Health Issue" sheds light on seeking professional help, behavioral techniques, and the importance of hygiene in managing this common but not normal health issue. While "Hygiene 101" provides valuable insights, it primarily focuses on pads, leaving out mention of alternative treatments like #pelvicfloor physical therapy or innovative solutions like @Flyte.

It's crucial to broaden our perspective on available options to treat the root cause of the incontinence versus continued coping, which can be costly and require ongoing caregiver assistance. #Pelvicfloorphysicaltherapy uses specialized and effective treatments to address the root causes of incontinence. Additionally, innovative solutions like Flyte offer fast, easy, clinically proven, and accessible alternatives for treating urinary incontinence from home.

Encouraging an approach to care that focuses on treatment solutions rather than solely relying on pads for managing urinary #incontinence is an area where continuous education for both ourselves and caregivers is essential.

 https://lnkd.in/eFtWHvDP

🔊 Breaking the Silence on Bladder Leaks: The Impact of Menopause and Aging on Urinary Incontinence in Women

In her recent article in @Femtech-world, our CEO Lydia Zeller challenges the historical silence surrounding the widespread issue of urinary incontinence.

Contrary to common misconceptions, urinary #incontinence is not an inevitable part of aging or motherhood. While #menopause doesn't directly cause incontinence, hormonal changes can worsen weaknesses in pelvic floor muscles.

Lydia emphasizes the need to break the silence, advocates for effective treatments beyond surgery or pads, and addresses the economic and #genderequity issues in #urinaryincontinence care.

Read the full article here: https://loom.ly/hYk-KYc 

#womenshealth #menopauseawareness #femtech #healthequality

Metric
Company Name	Flyte
Symbol
MSH ID	COM:FLYTETHERAPY
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Healthcare & Health Services
Country	US
Stage	Seed
Employee Count	12
Website	flytetherapy.com
LinkedIn	pelvital
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital	2.32M

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:FLYTETHERAPY

Flyte

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue